

Kerry Dwan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/917952/publications.pdf>

Version: 2024-02-01

72
papers

7,014
citations

159525

30
h-index

106281

65
g-index

76
all docs

76
docs citations

76
times ranked

10396
citing authors

#	ARTICLE	IF	CITATIONS
1	Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 99-105.	2.4	46
2	Reporting of Cochrane systematic review protocols with network meta-analyses: A scoping review. <i>Research Synthesis Methods</i> , 2022, 13, 164-175.	4.2	5
3	Advocating for evidence-informed decisions to make healthcare fit for each person. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 65-66.	1.7	2
4	Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic. <i>BMC Medicine</i> , 2021, 19, 46.	2.3	39
5	Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol. <i>F1000Research</i> , 2021, 10, 455.	0.8	2
6	Subcutaneous omalizumab for people with asthma. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
7	Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. <i>The Cochrane Library</i> , 2020, 2020, CD004449.	1.5	21
8	Risk of Bias 2 in Cochrane Reviews: a phased approach for the introduction of new methodology. <i>The Cochrane Library</i> , 2020, 10, ED000148.	1.5	17
9	Strengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. <i>PLoS Medicine</i> , 2020, 17, e1003344.	3.9	17
10	Video calls for reducing social isolation and loneliness in older people: a rapid review. <i>The Cochrane Library</i> , 2020, 2020, CD013632.	1.5	122
11	A cross-sectional audit showed that most Cochrane intervention reviews searched trial registers. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 86-91.	2.4	3
12	<i>NAT2</i> variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 293-305.	0.6	24
13	CONSORT 2010 statement: extension to randomised crossover trials. <i>BMJ: British Medical Journal</i> , 2019, 366, l4378.	2.4	306
14	Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2019, 108, 1-9.	2.4	6
15	CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 204.	2.5	10
16	Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. <i>BMJ: British Medical Journal</i> , 2018, 362, k3802.	2.4	83
17	The Use of Systematic Reviews When Designing and Reporting Surgical Trials. <i>Annals of Surgery</i> , 2017, 265, e35-e36.	2.1	9
18	Do systematic reviews still exclude studies with 'no relevant outcome data'? <i>BMJ: British Medical Journal</i> , 2017, 358, j3919.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). <i>Systematic Reviews</i> , 2017, 6, 142.	2.5	11
20	The Use and Reporting of the Cross-Over Study Design in Clinical Trials and Systematic Reviews: A Systematic Assessment. <i>PLoS ONE</i> , 2016, 11, e0159014.	1.1	34
21	Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. <i>Human Psychopharmacology</i> , 2016, 31, 268-285.	0.7	31
22	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. <i>The Cochrane Library</i> , 2016, , CD010383.	1.5	146
23	A systematic review and meta-analysis of Synacthen tests for assessing hypothalamic-pituitary-adrenal insufficiency in children. <i>Archives of Disease in Childhood</i> , 2016, 101, 847-853.	1.0	29
24	A third of systematic reviews changed or did not specify the primary outcome: a PROSPERO register study. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 46-54.	2.4	52
25	Vilanterol and fluticasone furoate for asthma. <i>The Cochrane Library</i> , 2016, 9, CD010758.	1.5	11
26	Bisphosphonate therapy for osteogenesis imperfecta. <i>The Cochrane Library</i> , 2016, 2016, CD005088.	1.5	173
27	Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to <i>The BMJ</i> . <i>BMJ Open</i> , 2016, 6, e010075.	0.8	10
28	Transcranial Doppler Screening in a Regional Care Network for Sickle Cell Disease in the United Kingdom. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 517-524.	0.3	4
29	Impregnated central venous catheters for prevention of bloodstream infection in children (the Tj ETQq1 1 0.784314,rgBT /Oyerlock 10 6.3 89)	0.3	4
30	How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee. <i>PLoS ONE</i> , 2016, 11, e0157883.	1.1	8
31	CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children. <i>Health Technology Assessment</i> , 2016, 20, 1-220.	1.3	19
32	The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-68.	1.3	22
33	Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. <i>The Cochrane Library</i> , 2015, 2015, MR000035.	1.5	152
34	Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. <i>The Cochrane Library</i> , 2015, , CD003147.	1.5	55
35	Selective reporting in clinical trials - an examination of discrepancy rates in pre-specified and reported outcomes in articles submitted to the <i>BMJ</i> . <i>Trials</i> , 2015, 16, .	0.7	2
36	Discrepancies in Outcome Reporting Exist Between Protocols and Published Oral Health Cochrane Systematic Reviews. <i>PLoS ONE</i> , 2015, 10, e0137667.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Mepolizumab versus placebo for asthma. , 2015, , CD010834.		40
38	Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. The Cochrane Library, 2015, , CD009841.	1.5	26
39	Deferred Consent for Randomized Controlled Trials in Emergency Care Settings. Pediatrics, 2015, 136, e1316-e1322.	1.0	44
40	Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. Behaviour Research and Therapy, 2015, 73, 151-164.	1.6	28
41	Reporting of Adverse Events in Surgical Trials: Critical Appraisal of Current Practice. World Journal of Surgery, 2015, 39, 80-87.	0.8	32
42	Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. Pharmacoeconomics, 2015, 33, 893-904.	1.7	7
43	Potentiators for cystic fibrosis "targeting the underlying molecular defect. Paediatric Respiratory Reviews, 2015, 16, 162-164.	1.2	0
44	Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. Pharmacoeconomics, 2015, 33, 13-23.	1.7	21
45	Outcome Discrepancies and Selective Reporting: Impacting the Leading Journals?. PLoS ONE, 2015, 10, e0127495.	1.1	61
46	Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment, 2015, 19, 1-130.	1.3	5
47	Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-134.	1.3	20
48	The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-192.	1.3	58
49	Sharing Individual Participant Data from Clinical Trials: An Opinion Survey Regarding the Establishment of a Central Repository. PLoS ONE, 2014, 9, e97886.	1.1	38
50	Evidence for the Selective Reporting of Analyses and Discrepancies in Clinical Trials: A Systematic Review of Cohort Studies of Clinical Trials. PLoS Medicine, 2014, 11, e1001666.	3.9	151
51	Bisphosphonate therapy for osteogenesis imperfecta. , 2014, , CD005088.		93
52	Exercise to Combat Depression"Reply. JAMA - Journal of the American Medical Association, 2014, 312, 2167.	3.8	2
53	Exercise for Depression. JAMA - Journal of the American Medical Association, 2014, 311, 2432.	3.8	143
54	A model-based correction for outcome reporting bias in meta-analysis. Biostatistics, 2014, 15, 370-383.	0.9	28

#	ARTICLE	IF	CITATIONS
55	Allopurinol for the treatment of chronic kidney disease: asystematic review. Health Technology Assessment, 2014, 18, 1-77, v-vi.	1.3	19
56	Exercise for depression. The Cochrane Library, 2013, 2013, CD004366.	1.5	859
57	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. , 2013, , CD003146.		39
58	Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ Open, 2013, 3, e002709.	0.8	37
59	Comparison of Randomized Controlled Trial Registry Entries and Content of Reports in Surgery Journals. Annals of Surgery, 2013, 257, 1007-1015.	2.1	47
60	Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias â€” An Updated Review. PLoS ONE, 2013, 8, e66844.	1.1	783
61	Exercise for depression. , 2012, , CD004366.		235
62	Inhaled magnesium sulfate in the treatment of acute asthma. The Cochrane Library, 2012, 12, CD003898.	1.5	35
63	Comparison of protocols and registry entries to published reports for randomised controlled trials. The Cochrane Library, 2011, 2011, MR000031.	1.5	166
64	Inhaled antibiotics for long-term therapy in cystic fibrosis. The Cochrane Library, 2011, , CD001021.	1.5	82
65	Comparison of protocols and registry entries to published reports for randomised controlled trials. Journal of Evidence-Based Medicine, 2011, 4, 194-194.	0.7	7
66	Antibiotic-impregnated ventriculoperitoneal shuntsâ€™ a multi-centre British paediatric neurosurgery group (BPNG) study using historical controls. Child's Nervous System, 2011, 27, 575-581.	0.6	56
67	Assessing the potential for outcome reporting bias in a review: a tutorial. Trials, 2010, 11, 52.	0.7	54
68	The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ: British Medical Journal, 2010, 340, c365-c365.	2.4	896
69	The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: A systematic review*. Critical Care Medicine, 2009, 37, 702-712.	0.4	133
70	Reporting of clinical trials: a review of research funders' guidelines. Trials, 2008, 9, 66.	0.7	33
71	Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PLoS ONE, 2008, 3, e3081.	1.1	1,142
72	Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. The Cochrane Library, 0, ,.	1.5	3